Saturday, October 8, 2022

Luke Meier on Achieving True Strict Product Liability (But Nor for Plaintiffs with Fault)

Luke Meier, Professor of Law at Baylor Law School, has posted to SSRN his manuscript, Achieving True Strict Product Liability (But Not for Plaintiffs with Fault).  Here is the abstract:

Under modern tort law, the strict product liability cause of action does not impose true strict liability. This Article suggests that this development can be traced to an analytical difficulty: How to prevent a plaintiff with fault from being able to take advantage of the strict liability standard? Courts have not developed a satisfactory doctrine that both imposes true strict product liability on manufacturers while simultaneously preventing plaintiffs with fault from recovery on this claim. In the absence of a better idea, courts have (mostly) retreated from a true strict product liability standard. This Article offers a solution to this analytical riddle: A simple change to the current comparative fault jury instructions would allow jurisdictions to impose strict product liability on manufacturers while simultaneously preventing plaintiffs with fault from recovering on a strict product liability claim. This is all that is necessary for jurisdictions that are inclined to put the “strict” back in the strict product liability cause of action.

October 8, 2022 in Mass Tort Scholarship, Products Liability | Permalink | Comments (0)

Tuesday, September 27, 2022

Joseph William Singer on Personal Jurisdiction and Choice of Law

Joseph William Singer, Bussey Professor of Law at Harvard Law School, has posted to SSRN his article, Hobbes & Hanging: Personal Jurisdiction v. Choice of Law, 64 Ariz. L. Rev. (forthcoming 2022).  Here is the abstract:

When conduct in one state causes injury in another state, and the law at the place of injury is more favorable to the victim than the law of the place of conduct, what law applies? Where can suit be brought? The traditional answers are that the law of the place of injury applies but that it may be unconstitutional to sue the tortfeasor in the courts at the place of injury because all the tortfeasor's conduct took place outside the forum. Scholars have long criticized this contradiction, and this Article argues that they are right to do so. If we focus on choice-of-law theory and the emerging choice-of-law rules in the Third Restatement of Conflict of Laws, we see that the argument for applying the plaintiff-protecting law of the place of injury is strong. This Article explains and develops that argument, and it gives us reason to reject the idea that the place of injury courts have no personal jurisdiction over the defendant. Hobbes taught us that the first job of government is to protect us from harm at the hands of others and, as long as it is objectively foreseeable that the conduct could have caused harm in the place of injury, there is no fundamental unfairness or constitutional prohibition on applying place of injury law. If that is so, it is irrational not to allow victims to sue at home where they have been injured. Nor is personal jurisdiction unfair to the defendant. It is time to bring choice-of-law doctrine and personal jurisdiction law more in line with each other, and the right way to do so is to adopt an approach that ensures that victims have civil recourse in their home courts against those who stand across the border engaged in acts that intentionally or predictably cause harm there.

 

September 27, 2022 in Mass Tort Scholarship | Permalink | Comments (0)

Monday, September 26, 2022

Bradt, Clopton, and Rave on Dissonance and Distress in Bankruptcy and Mass Torts

Andrew Bradt, Associate Dean, J.D. Curriculum and Teaching, Faculty Director of the Civil Justice Research Initiative, and Professor of Law at UC Berkeley School of Law; Zachary Clopton, Professor of Law, Northwestern University Pritzker School of Law; and D. Theodore Rave, Professor of Law, University of Texas at Austin School of Law have posted to SSRN their article, Dissonance and Distress in Bankruptcy and Mass Torts, Fordham L. Rev. (forthcoming).  Here is the abstract:

This Essay reviews the highly successful 2022 Fordham Law Review symposium on the Intersection of Aggregate Litigation and Bankruptcy. The symposium brought together judges, scholars, and practitioners who work on multidistrict litigation (MDL), bankruptcy, or both. The symposium was successful because it brought these groups into conversation at a time when high profile mass tort defendants are increasingly turning to bankruptcy to escape MDL, while others involved in the MDL process seek to keep them in. It also was successful—and distressing, in our view—because it highlighted disturbing trends in complex litigation.

This Essay makes two principal observations. First, we document the different ways that MDL and bankruptcy players view their institutions. Even if they share similar goals of achieving lasting resolutions to mass tort disputes, they come from different starting points and stress different values. Civil litigators, including those in MDLs, hue to traditional notions of victims, liability, and adversarial adjudication. Bankruptcy lawyers, meanwhile, focus more on creditors, preserving value, and moving on. Second, we demonstrate that criticisms of MDL’s treatment of individual plaintiffs—both in the symposium and outside it—are being leveraged by defense-side interests seeking to promote bankruptcy as a means of resolving mass torts. Taken together, these two observations reveal a dissonance between the seemingly pro-plaintiff criticisms of MDL and the seemingly pro-defendant use of those criticisms to denigrate MDL in favor of bankruptcy.

September 26, 2022 in Aggregate Litigation Procedures, Mass Tort Scholarship, Procedure | Permalink | Comments (0)

Saturday, September 24, 2022

Linda Mullenix on Assessing the Impact of The Principles of the Law of Aggregate Litigation

Linda Mullenix, Morris & Rita Altas Chair in Advocacy at University of Texas at Austin School of Law, has posted to SSRN her book chapter, Aggregationists at the Barricades: Assessing the Impact of The Principles of the Law of Aggregate Litigation, in American Law Institute -- A Centennial History (Andrew S. Gold and Robert W. Gordon eds., Oxford University Press forthcoming 2023 ).  Here is the abstract:

In 2004 the American Law Institute began work on THE PRINCIPLES OF THE LAW OF AGGREGATE LITIGATION, finally published in 2010. The Principles was addressed to legislatures, administrative agencies, attorneys, private actors, and courts concerning multiparty, multiforum litigation. A purpose of the Principles was to suggest best practices for these institutions and actors.

This essay describes the Principles in the historical context when complex litigation began to dominate federal dockets in the 1980s. It discusses the emergence of a cohort of aggregationists dedicated to liberalizing federal procedure to support, enhance, and encourage the speedy and efficient resolution of complex litigation. The Principles built upon a longstanding ALI concern with the burgeoning and rapidly changing judicial crisis relating to the resolution of complex litigation. The Principles suggested substantial changes in existing class action jurisprudence and judicial case management, recommending more robust embrace of liberalized aggregative procedures. Initially, the Reporters advocated for a root-and-branch revision but, as the essay documents, the final Principles reflected more modest compromises. The essay thoroughly canvasses the proposed recommendations and the subsequent embrace of the proposals.

This essay concludes that while the Principles project has left its mark, courts and legislative bodies still have not addressed or resolved many issues the Principles identified. Since publication most judges seem comfortable with prevailing jurisprudence and not especially interested in rewriting procedural doctrine governing complex litigation. The Principles has not resulted in a root-and-branch revision of aggregate procedure. Rather, reception of the Principles suggests that a more incremental approach to legal reform has prevailed, and the efforts of the avid aggregationists must await another day.

Apart from questions whether the Principles fulfilled its stated purpose, this essay explores fundamental questions about the Institute’s role in moving the law in certain directions based on the goals of committed actors. On one interpretation, the Principles represented a well-intended effort to provide judges with guidance “where there was little established law.” On another, perhaps more problematic view, the Principles represented the desires of actors who, frustrated by judicial resistance to aggregate litigation, used ALI auspices to change the law in a desired direction. These questions go to the heart of the ALI’s role in guiding attorneys, judges, and rulemaking bodies in furtherance of civil justice. Whether the liberalization of aggregate procedure is a desirable goal is a normative question that the ALI Principles project assumed but did not address.

September 24, 2022 in Aggregate Litigation Procedures, Mass Tort Scholarship, Procedure | Permalink | Comments (0)

Friday, September 23, 2022

Catherine Sharkey on Common Law Tort as Transitional Regulatory Regime and Climate Change Litigation

Catherine Sharkey, Segal Family Professor of Regulatory Law and Policy at NYU School of Law, has posted to SSRN her book chapter, Common Law Tort as a Transitional Regulatory Regime: A New Perspective on Climate Change Litigation, in Climate Liberalism: Perspectives on Liberty, Property, and Pollution (Palgrave: Jonathan Adler ed.) (2022 Forthcoming).  Here is the abstract:

This book chapter explores how common law (state or federal) tort law evolves to fill regulatory voids. Particularly in areas that pose emerging, and incompletely understood, health and safety risks, common law tort liability holds out the potential for a dynamic regulatory response, one that creates incentives to develop additional information about potential risks and stimulates innovation to mitigate and/or adapt to these risks. In this temporal model, common law tort plays an essential role in transition, allowing for experimentation with various risk-minimization methods and remedial approaches until optimal approaches emerge which could then be enshrined in more uniform regulations.

The chapter identifies and assesses this dynamic, information-forcing role for common law tort liability in the realm of climate change litigation. In this model, common law tort, rather than a relic of the past, emerges as relevant to the future of environmental risk regulation, as indeed superior to legislation and/or regulation in terms of addressing newly-emergent risks. Moreover, the model suggests that the interaction between common law tort and federal statutes and regulations will remain interactive and dynamic over time.

The chapter then uses climate change litigation as a case study to shed light on the expansion of common law public nuisance to fill a regulatory void in this area, revealing the modern relevance of common law tort in environmental law. The chapter concludes with a preliminary evaluation of the extent to which experimentation among states and municipalities with regard to various adaptation measures fits the optimal model of common law tort in transition, with a final gesture toward forces at play that may stymie the common law’s evolutionary impulses.

September 23, 2022 in Environmental Torts, Mass Tort Scholarship, Regulation | Permalink | Comments (0)

Sunday, February 6, 2022

Rabin and Engstrom on No-Fault Compensation for Tobacco and Opioid Victims

Professors Robert Rabin and Nora Freeman Engstrom of Stanford Law School have posted to SSRN their article, The Road Not Taken: Perspectives on No-Fault Compensation for Tobacco and Opioid Victims, 70 DePaul L. Rev. 395 (2021).  Here is the abstract:

Cigarettes and prescription painkillers have both killed millions of Americans and diminished the lives of tens of millions more. This wreckage has generated waves of prolonged litigation—and, in fact, the evolution of this litigation has been strikingly similar. In both tobacco and in opioids, lawsuits were initially filed by individual victims of defendants’ tortious conduct. But in both instances, one-off suits saw virtually no success, foundering on vast resource disparities and a widespread perception that plaintiffs (smokers on the one hand, “addicts” on the other) were partly or mostly to blame. In time, plaintiffs adapted. States and cities took the reins, and these public actors initiated their own suits. This handoff (from private plaintiffs to public ones) succeeded in many respects. But it relegated individual victims to the sidelines and—crucially—consigned their quest for compensation to the back burner.

In this Essay, we zero in on this compensation question. We explore the fact compensatory claims got pushed aside and note that these claims have generally remained on the periphery. We further observe that, after the tort system left individual victims conspicuously empty-handed, support might have coalesced around the creation of a no-fault compensation scheme for tobacco or opioid-related harms. Yet, discussion of such a scheme has been quiet—and concrete action toward the creation of such a system has been notably non-existent. Why? We chalk this omission up to three stubborn realities. First, the will and capacity to strike a political compromise of this magnitude is lacking. Second, existing no-fault schemes have mixed scorecards, at best. And third, both tobacco and opioid victims pose particular challenges, as a perception that these individuals have contributed to their own harm has undermined any prospect of compensation through a no-fault scheme, just as surely as it dimmed plaintiffs’ prospects for recovery through tort.

February 6, 2022 in Mass Tort Scholarship, Tobacco | Permalink | Comments (0)

Sunday, August 8, 2021

Law & Contemporary Problems Issue In Memoriam: Professor Francis McGovern

The journal, Law & Contemporary Problems, has published an an issue In Memoriam: Francis McGovern, entitled, "Innovations in Complex Litigation and Settlement."  Published authors include the following: Lynn Baker (Texas Law); David Bernick (Kirkland & Ellis); Stephen Burbank (Penn Law); Elizabeth Cabraser (Lieff Cabraser); Sean Farhang (Berkeley Law); Brian Fitzpatrick (Vanderbilt Law); Gary Friedman; Myriam Gilles (Cardozo Law); Deborah Hensler (Stanford Law); Samuel Issacharoff (NYU Law); Robert Klonoff (Lewis & Clark Law); David Levi (Duke Law); Richard Marcus (UC Hastings Law); Troy McKenzie (NYU Law); Senior Judge Dan Polster (N.D. Ohio); D. Theodore Rave (Texas Law); Judith Resnick (Yale Law); Christopher Seeger (Seeger Weiss); Charles Silver (Texas Law); and former Judge Vaughn Walker (N.D. Cal.).  Professor McGovern is also credited as co-author for an article for which he had the original idea and was very involved in assembling the central argument.  

August 8, 2021 in Aggregate Litigation Procedures, Mass Tort Scholarship | Permalink | Comments (0)

Monday, July 12, 2021

Lytton on Guns and New York's Recently Amended Public Nuisance Statute

Professor Tim Lytton has published an article in The Conversation on New York's recently amended public nuisance statute. Here's a link!

July 12, 2021 | Permalink | Comments (0)

Wednesday, June 2, 2021

The Failed Roundup Gambit

*First published as Multidistrict Litigation and Bayer's Roundup Gambit in Westlaw Today/Reuters Legal

Bayer and the plaintiffs’ lawyers suing it over its popular weed killer, Roundup, are playing a high-stakes, billion-dollar chess match. Like most corporate defendants in Bayer’s position, it wants lawsuits to end.

But finality eludes Bayer for two reasons.

First, non-Hodgkin’s lymphoma, the disease several juries linked to Roundup’s active ingredient glyphosate, doesn’t develop overnight. It takes a while, often 10-15 years after exposure. Yanking Roundup off the market today would still leave Bayer with at least another decade of litigation.

Second, Roundup makes Bayer lots of money. Sticking a warning label on it would hurt the company’s bottom line. Why would consumers risk cancer to kill dandelions?  

Enter Bayer’s elaborate gambit.

A3F681CE-D0F9-4383-A1A8-CDA00948D1B8_1_201_a

Step one: preemption.

Bayer accurately predicted that the Ninth Circuit (despite a relatively conservative panel) would reject its argument that the Federal Insecticide, Fungicide, and Rodenticide Act, fondly known as FIFRA, preempts claims that it failed to warn weed exterminators about the risks of non-Hodgkin lymphoma. In May, the majority in Hardeman v. Bayer ruled that Mr. Hardeman’s failure-to-warn claim was “equivalent to” and “fully consistent with” FIFRA and thus not preempted under the Supreme Court’s 2005 precedent, Bates v. Dow Agrosciences LLC.

While it awaited the Hardeman decision, Bayer worked to manufacture a circuit split elsewhere that might tempt the Supreme Court to weigh in and reconsider Bates. For that, it tapped Dr. John Carson, a Georgia plaintiff who alleged a type of cancer that science has not linked to Roundup, malignant fibrous histiocytoma. Siding with Bayer, the Southern District of Georgia dismissed Dr. Carson’s failure-to-warn claim because FIFRA preempted it. Bayer won.

But that short-term win undermined its overarching goal. So, Bayer sacrificed by entering into a settlement of sorts with Dr. Carson: for $100,000, he would appeal the dismissal and the preemption ruling. Winning on preemption before the Eleventh Circuit would increase the likelihood of Supreme Court review, at least by a little, despite Bayer’s sly pay-to-appeal scheme.

The possibility of a circuit split and complete preemption serves another purpose, too. It acts like a sword of Damocles endangering plaintiffs who haven’t yet settled, haven’t yet sued, or haven’t yet developed non-Hodgkin lymphoma despite using Roundup. Plaintiffs won all three jury trials to date, notwithstanding a bifurcated trial structure that tends to favor defendants. Compared with the mature asbestos cases that led to the derailed Amchem settlement, the Roundup suits are barely entering grade school. But plaintiffs’ fortunes can turn.

Step two: certify a futures class.

Pressing the slimmest of advantages (after all, the Supreme Court grants certiorari in only around 3.4% of civil cases per year), Bayer teamed up with the same amenable plaintiffs’ counsel whose attempt at certifying a futures class last summer ended in a swirl of controversy and a withdrawn motion. Presenting a second, then a third futures class proposal, they purport to shelter three groups of class members from preemption’s peril: (1) people diagnosed with non-Hodgkin lymphoma after Roundup exposure that haven’t hired lawyers yet; (2) people who have used Roundup but haven’t yet developed non-Hodgkin lymphoma, and (3) all of their spouses, parents, and dependent children—collectively, the “derivative claimants.”

But the preemption refuge and the benefits last a mere four years. And they come at a steep price. In exchange for notice, medical help, and some streamlined compensation, class members must give up punitive damages and medical monitoring claims, as well as bind themselves (with little wiggle room) to a seven-member science panel’s verdict about whether glyphosate can cause non-Hodgkin lymphoma.

After the four-year détente lifts, few plaintiff’s lawyers would litigate Roundup claims in the face of such weighty impediments.

For the gambit to work, the judge must certify the class. But Judge Vince Chhabria is no pawn and he declined to do so. His brief six-page opinion followed a day-long hearing transparently livestreamed in Brady-bunch boxes for a clamoring public to see.

In both the hearing and the opinion, Judge Chhabria challenged the settlement’s upside: Four years of medical monitoring for a disease with a 10-15 year latency period is “far less meaningful than the attorneys suggest.” Those with later diagnoses “will not be able to request compensation from the fund,” he wrote.

As Judge Chhabria pointed out, problems with the proposed futures class abound, including, most centrally, the constitutionality and utility of notice and the hamstrung tort claims. For plaintiffs, the downsides require “major sacrifices,” he explained.

First, on notice, what value does the settlement add that a well-incentivized plaintiffs’ bar lacks? The proposal allocates up to $55 million for settlement administration and notice costs for five months. Yet, over two years ago, the Wall Street Journal reported that plaintiffs’ lawyers spent an estimated $77.8 million to advertise Roundup lawsuits for eight months.

Setting aside the constitutional impossibilities of notifying future spouses and unborn children, what people need is meaningful information at a meaningful time. Noise fills the world. Our bandwidth is limited.

A Roundup user without cancer is far more likely to mindlessly scroll through whatever notices pop up than to engage and investigate. Someone newly diagnosed with non-Hodgkin lymphoma, however, is hungrily Googling for information and answers.

Second, consider what plaintiffs bestow upon Bayer by giving up punitive damages—absolution. But the alleged bad behavior continues. Imagine fining attempted murderers and freeing them to continue their spree. Roundup still lines store shelves and if it does what plaintiffs contend, it will endanger public health for decades to come.

Third, class members must litigate under the umbrella of the science-panel’s findings. “But the reason Bayer wants a science panel so badly is that the company has lost the ‘battle of the experts’ in three trials,” wrote Judge Chhabria.

It is possible that the parties will attempt yet another class settlement geared toward only those Roundup users who have non-Hodgkin lymphoma but no lawyer. Still, what is the upside to the court? Frame it in terms of class superiority: Is certifying a class better than the other ways courts can fairly and efficiently resolve plaintiffs’ claims? Judge Chhabria already faces a scrum of centralized lawsuits. And certifying a class will not end disputes.

Despite a settlement class in the NFL Concussion cases, litigation continually bubbles up, most recently in terms of Black players alleging class settlements show bias. Despite a settlement class in BP’s Deepwater Horizon Oil Spill, over 6,300 clean-up workers have continued to sue over latent injuries like blood-related cancers from chemical dispersants through the settlement’s back-end litigation option. Despite a settlement class in Diet Drugs, 50,000 would-be class members opted out, claims overwhelmed the class, and litigation before the same judge continues today—21 years later.

There is no neat end game in sight for Bayer or the courts, even as it debuts its five-point plan to reassure stockholders. Remanding cases once common discovery ends and taking up the old saw of trial may sound antiquated in the face of futuristic procedures that promise the next best thing. Yet, it has worked for centuries. Perhaps it’s just that the weeds always seem greener on the other side.

June 2, 2021 in Mass Tort Scholarship, Preemption | Permalink | Comments (0)

Tuesday, February 16, 2021

George Mason Law & Economics Center Symposium on the Economics and Law of Civil Remedies: Developments in Damages and Nationwide Injunctions

The Law & Economics Center at George Mason University Scalia Law School is hosting on online Symposium on the Economics and Law of Civil Remedies: Developments in Damages and Nationwide Injunctions from 10:00 a.m. to 2:55 p.m. EST on Friday, February 19, 2021.  Registration is free.  Here is the agenda:

10:00 – 10:05 am Opening Remarks

Donald J. Kochan, Professor of Law and Deputy Executive Director, Law & Economics Center
George Mason University Antonin Scalia Law School

10:05 – 11:05 am
Panel 1: An Update on the Ongoing Debate over Nationwide Injunctions, Especially with a Change in Presidential Administration
Samuel L. Bray, Professor of Law, The Notre Dame University Law School
Scott A. Keller, Former Solicitor General
State of Texas (2015-2018)
Amy Marshak, Senior Counsel, Institute for Constitutional Advocacy and Protection and Adjunct Professor of Law, Georgetown University Law Center
Michael T. Morley, Associate Professor, Florida State University College of Law
Moderator: Trevor N. McFadden, District Judge, US District Court for the District of Columbia

11:15 am – 12:15 pm
Panel 2: Developments in Punitive Damages
Eric D. Holland, Owner and Partner, Holland Law Firm, LLC
Evan M. Tager, Partner, Mayer Brown
W. Kip Viscusi, University Distinguished Professor of Law, Economics, and Management
Co-Director, PhD Program in Law and Economics
Vanderbilt Law School
Navan Ward, Principal, Beasley Allen
Moderator: Harris L Hartz, Circuit Judge, US Court of Appeals for the Tenth Circuit

12:45 – 1:45 pm
Panel 3: The Controversy over Trends in High Damage Awards: A Discussion on Causes and Consequences
David Ball, Trial Consultant, Malekpour & Ball Litigation Strategy
Mark A. Behrens, Co-Chair, Public Policy Practice Group, Shook Hardy & Bacon
John H. Beisner, Partner, Litigation, Mass Torts, Insurance, and Consumer Litigation
Skadden, Arps, Slate, Meagher & Flom LLP
Laura Frank Sedrish, Partner, Jacoby & Meyers
Moderator: Brock A. Swartzle, Judge, Michigan Court of Appeals

1:55 – 2:55 pm
Panel 4: Issues in Documenting and Calculating Damages: The Debate Over Medical Financing and “Phantom” Damages
Nicholas C. Johnson, Of Counsel, Cohen Milstein Sellers & Toll PLLC
Drew LaFramboise, Partner, Ashcraft & Gerel
Lee Mickus, Partner, Evans Fears & Schuttert LLP
Caitlin F. Saladrigas, Partner, Holland & Knight
Moderator: William C. Mims, Justice, Virginia Supreme Court

February 16, 2021 in Conferences, Procedure, Punitive Damages | Permalink | Comments (0)

Friday, January 1, 2021

AALS Section on Litigation Panel on the Growth of Third-Party Litigation Finance: Opportunities and Challenges

At the online 2021 Annual Meeting of the Association of American Law Schools, the AALS Section on Litigation program will be the "The Growth of Third-Party Litigation Finance: Opportunities and Challenges":

Over the last decade, third-party litigation finance in the United States has quickly grown into a $10 billion industry.  Third-party litigation finance has been praised for increasing access to justice and reducing variations in litigant resources and risk tolerance, but concerns have been raised about champerty, less meritorious litigation, and effects on lawyer independence and client control.  This program will explore third-party litigation finance with attention to contested issues such as fee splitting, claim assignment, aggregate litigation, and attorneyclient privilege.  The program will explore proposals such as disclosing third-party litigation finance in litigation and permitting non-lawyer ownership or investment in law firms.

The panel will take place from 2:45 p.m. to 4:00 p.m EST on Tuesday, January 5, 2021, and I will serve as moderator for the nationally leading panel of speakers:

  • John Beisner, Partner and Leader, Mass, Torts, Insurance and Consumer Litigation Group, Skadden, Arps, Slate, Meagher & Flom LLP;
  • Jonathan Molot, Professor of Law, Georgetown University Law Center, and Co-Founder and Chief Investment Officer, Burford Capital;
  • Victoria Shannon Sahani, Associate Dean of Faculty Development and Professor of Law, Arizona State University Sandra Day O'Connor College of Law;
  • Anthony Sebok, Professor of Law and Co-Director, Jacob Burns Center for Ethics in the Practice or Law, Yeshiva University Cardozo School of Law; and
  • Maya Steinitz, Professor and Bouma Family Fellow in Law, University of Iowa College of Law.

January 1, 2021 | Permalink | Comments (0)

Wednesday, December 23, 2020

Civil Justice Fest Panel Videos from the Law & Economics Center at George Mason University Scalia Law School

The Law & Economics Center at George Mason University Scalia Law School has posted online the videos for all of the panels for Civil Justice Fest: A Month of Dialogues on the Most Pressing Civil Justice Issues.

December 23, 2020 in Aggregate Litigation Procedures, Procedure, Products Liability | Permalink | Comments (0)

Tuesday, December 22, 2020

Plaintiffs' Attorney Shanin Specter Critical of Certain MDL Practices

Article in Legal Newsline -- Plaintiffs lawyer rips colleagues over multidistrict litigation fees, pressure tacticsby Daniel Fisher:

Federal multidistrict litigation, a procedure intended to resolve mass-tort lawsuits fairly and efficiently, has mutated into an unethical moneymaking machine for lawyers that is badly in need of reform, a prominent plaintiff attorney says as he prepares to lobby for changes.

Conservatives and tort-reform groups have long criticized MDLs as a form of asymmetric warfare against defendants in which thousands or even tens of thousands of lawsuits are gathered before a single federal judge who frequently sets settlement, not trial on the merits, as the goal. But it is unusual for a plaintiff attorney to lodge such a fierce critique on the procedure that has earned his colleagues billions of dollars in fees.

December 22, 2020 in Aggregate Litigation Procedures, Procedure, Products Liability | Permalink | Comments (0)

Law360 Names King & Spalding a Defense Product Liability Group of the Year

Article on Law360 -- Product Liability Group Of The Year: King & Spalding, by Daphne Zhang:

King & Spalding's product liability group notched victories this year, such as erasing a $454 million defective medical equipment verdict against Kimberly-Clark Corp. at the Ninth Circuit and helping Honda toss $1.7 billion worth of defect claims, landing the group a spot among Law360's 2020 Product Liability Groups of the Year.

Andy Bayman, head of the firm's trial and global disputes practice group and a product liability lawyer himself, told Law360 that product liability is "a big and important practice" of the firm. The practice group's 170 lawyers, with more than 60 partners, work from nine of the firm's offices, including locations in Atlanta, Houston, Los Angeles and New York.

December 22, 2020 | Permalink | Comments (0)

Tuesday, October 13, 2020

MDLs & Class Actions: A Discussion with Elizabeth Burch & Chris Seeger

7cb5b487-52fc-47a3-bd80-0647a1dec38f

For the mass tort and MDL enthusiasts of the world, I hope you'll be able to join me, Chris Seeger, and Judge John Koeltl on Tuesday, October 20, at 2pm EST via zoom for a discussion hosted by NYU's Civil Justice Center.

We'll be talking about MDLs and how to improve them, with topics ranging from so-called claims census, the need for remands, leadership's ethical obligations to nonclient plaintiffs, the role of the MDL judge in non class MDLs (and during settlements), and ways to reinvigorate the jury trial in the midst of the covid19 pandemic.  I'll also be highlighting some of the critiques that I have of the system as well as ways that we might address them.

We plan to take audience questions after each of our topics and I'd love to hear from you.

Registration is free (I think) and has been approved for 2 hours of CLE credits in the areas of professional practice.  

October 13, 2020 in Class Actions, Conferences, Current Affairs, Mass Tort Scholarship | Permalink | Comments (0)

Monday, May 25, 2020

Judicial Adjuncts in Multidistrict Litigation: from Special Masters to Claims Administrators

As our readers tend to know, MDLs prioritize efficiency.  That is, after all, what the statute was designed to do--promote efficient resolution. 

But what's often unknown is the best way to promote efficiency and whether efficiency might have unintended consequences.

Back in 2019, the American Bar Association (ABA) called for courts to appoint special masters regularly in MDLs. Its report claimed that multidistrict proceedings in particular could “benefit from specialized expertise,” and that “[e]ffective special masters reduce costs by dealing with issues before they evolve into disputes and by swiftly and efficiently disposing of disputes that do arise.”

The ABA’s resolution thus urged judges to appoint special masters in complex cases at “the outset of litigation” and permit them to do everything from oversee discovery and pretrial litigation to conduct trials based on parties’ consent, allocate settlements, and administer claims. Failing to do so, it cautioned, “[r]egardless of the reason,” “may disserve the goal of securing ‘a just, speedy, and inexpensive determination.’”  Neither this reproach nor the ABA’s empirical claims included empirical support, however.

My co-author, Margie Williams, and I set out to investigate. But we didn't just look into special masters, we considered everyone that judges allocate power or authority to in MDLs: magistrate judges, claims administrators, lien resolution administrators, and even banks. We posted our article, Judicial Adjuncts in Multidistrict Litigation, on SSRN today and the paper will appear in Columbia Law Review this December. But for those of you who'd prefer the quick version, here's a summary of our findings:

Proceedings with special masters lasted 66% longer than those without them.

Using a duration model allowed us to investigate this statistic further by controlling for a proceeding's outcome (settlements uniformly took longer), personal-injury claims (which likewise took longer), and the number of actions in a proceeding (the more actions, the longer the proceeding lasted).

Nevertheless, appointing a judicial adjunct of any kind made the proceedings continue longer than they otherwise would, all else being equal. 

Designating a judicial adjunct meant that the proceeding was 47% less likely to end. And for every additional adjunct appointed, there was an 11% decrease in the probability of a proceeding ending.

Of course, magistrate judges are salaried court employees. Appointing them does not add to parties' cost. But parties must pay for special masters, claims administrators, etc., which raises questions about costs. After all, Rule 1 isn't just concerned with efficiency; it's concerned with securing "the just, speeding, and inexpensive determination of every action and proceeding." Here, however, we ran into a roadblock:

Compensation information was either undisclosed or affirmatively sealed for 62% of private adjunct appointments.

Some of the payments that we could unearth ran into the millions. In the Actos proceeding, for instance, Special Master Gary Russo charged over $4.7 million and Deputy Special Master Kenneth DeJean charged over $1.3 million. And special settlement masters Ken Feinberg, Michael Rozen, John Trotter, and Cathy Yanni collectively charged over $9.4 million to administer the Zyprexa settlement. 

Even though we couldn't always identify the amounts charged, we were able to discern that plaintiffs alone bore the costs for 54% of private adjuncts, meaning that in over half the the appointments, defendants did not contribute.

To try and figure out why judges appoint judicial adjuncts if proceedings with adjuncts cost more and last longer, we conducted confidential interviews with plaintiff and defense attorneys, special masters, claims administrators, magistrate judges, and district court judges with a wealth of MDL experience.

Interviews revealed two competing narratives. In one version, courts outsourced to effectively manage complex cases behind the scenes and closely monitored those appointed. In the other, repeat players in both the bar and the private-adjunct sector came to mutually beneficial arrangements that exposed real-life problems over capture, self-dealing, bias, transparency, and ad hoc procedures.

You'll just have to read the paper for those juicy tidbits (and there are plenty). They can be found in Part IV.  

We did create some pretty fascinating data visualizations that were just too detailed to work in the article, so I thought I might share those with you here instead. I'd just ask that before you quibble with our categorizations that you read the caveats and explanations that we provide in the paper itself. But of course we'd welcome feedback.  The following visualization provides what I think of as a snapshot of the lifecycle of an MDL, with critical events like centralization, settlement, and dispositive decisions included alongside judicial adjunct appointments, which are also color coded.  A different version of the graphic that's less "busy" appears in the paper. Clicking on the graphic will bring up an interactive version that allows you to see more details.

Lifecycle of MDL with Judical Adjuncts

As our readers surely know, it's difficult to pinpoint all of the factors that make a proceeding complex. Nevertheless, we tried!  Of course, we can't measure things like the difficulty of proving causation, but we did code for the way the proceedings were resolved (as judged by the majority of the actions--some individual settlements may have occurred, for instance, even in proceedings we marked as "defense wins"); whether the proceeding included personal-injury allegations, whether the defendants were related to one another (e.g., parent-subsidiary), and the number of actions in the proceeding.  

The following visualization includes some of those factors, pairing them alongside the days to a proceeding's closure, the number of actions in the proceeding, and the number of judicial adjuncts in the proceeding.  Again, we provide some important qualifiers in the paper itself.  

Here are two: First, we use the official closed date rather than the settlement date because many of our adjuncts were appointed post-settlement to help administer the settlement program. Thus, the date the the court formally closes the proceeding remains an important milestone. (You can still see settlement dates in the above graphic.)

Second, in some proceedings, the number of actions filed on the court docket may well undercount the actions affected by the MDL.  This is because global settlements often include state-court plaintiffs and unfiled claims, judges have begun to create shadow dockets, and parties institute tolling agreements so that claims do not actually appear on the docket. Unfortunately, systematic data is not publicly available to remedy these deficiencies. 

Even with those caveats in place, you might find this interesting--I certainly did:

MDL Complexity - Outcomes  PI  Actions  Adjuncts

Again, clicking on the graphic above will open an interactive version. 

I hope this post is enough to interest you in the paper itself. We offer a number of theoretical contributions and suggestions to help chart a path forward that may interest MDL judges and attorneys. 

As always, we welcome your comments.

May 25, 2020 in Aggregate Litigation Procedures, Class Actions, Mass Tort Scholarship, Procedure, Products Liability, Settlement, Vioxx, Zyprexa | Permalink | Comments (0)

Thursday, May 14, 2020

The Commonality of Causation

I hope everyone is navigating the pandemic healthy and (relatively) sane. I know I have not posted in a while, but I want to share with everyone a lecture I gave at Ohio Northern University School of Law discussing the causation element in mass tort cases. I focus specifically on the Roundup MDL in the Northern District of California. I really appreciate the sophisticated audience this blog attracts. Accordingly, I would love to hear your comments on the lecture, which can be found here. Below is the abstract:

This essay, a version of which was given as the inaugural Goldman Endowed Lecture at Ohio Northern University School of Law, discusses the treatment of causation in class actions, multidistrict litigation, and similar collective litigation. Causation is a ubiquitous element of civil claims, and typically it is treated as an individual element of a claim because it is dependent on the circumstances of each individual claimant. Even if the conduct at issue in litigation is “common,” or the same, for a group of claimants, whether that conduct caused harm to a specific claimant will depend on the unique circumstances of that claimant. For that reason, courts have often refused to certify class actions, or have otherwise been reluctant to utilize collective procedures, where issues of causation predominate the proceedings. It is thought that in such cases plaintiffs are entitled to a more tailored, individualized hearing to accurately assess causation consistent with due process. This essay questions this common-sense notion that the issue of causation is an “individual” issue and argues that causation is actually much more “common” when one examines the causation element and its proof in greater depth. The essay concludes by suggesting ways in which the “commonality” of causation can be addressed in litigation to better fulfill the deterrence and compensation objectives of the litigation.

May 14, 2020 | Permalink | Comments (0)

Tuesday, May 5, 2020

Congressional Consideration of Liability Protections for Coronavirus

Article in the Wall Street Journal -- Liability Shield Is Next Coronavirus Aid Battle in Congressby Siobhan Hughes and Jacob Gershman.

May 5, 2020 | Permalink | Comments (0)

Thursday, February 13, 2020

Bayer Strives to Settle Lawsuits While Roundup Still on the Market

Article in the Wall Street Journal -- Bayer Strives to End Lawsuits Over Roundup—While Still Selling It, by Laura Kusisto, Ruth Bender, and Jacob Bunge.

February 13, 2020 in Products Liability, Settlement | Permalink | Comments (0)

Wednesday, January 22, 2020

Symposium on New Frontiers in Torts: The Challenges of Science, Technology & Innovation at Southwestern Law School in Los Angeles

The Southwestern Law Review Symposium, New Frontiers in Torts: The Challenges of Science, Technology, and Innovation, will take place on Friday, February 7, 2020 at Southwestern Law School in Los Angeles.  The Symposium is the inaugural event of Southwestern Law School’s Panish Civil Justice Program, which was endowed by one of the country’s leading trial lawyers, Southwestern Law School alumnus Brian Panish.  The Symposium's first panel will focus on tort practice, addressing an eclectic mix of subjects ranging from predictive analytics and e-discovery to scientific evidence and the cognitive science of jury persuasion.  Next, panel two will examine recent trends in financing lawsuits and proposals for changing non-lawyer relationships with law firms.  In panel three, the discussion turns to new forms of tort litigation, including recent developments in multidistrict, complex, class, and toxic tort actions such as the opioid mass litigation, among others.  The fourth panel will examine tort theory, analyzing both how traditional theories can deal with new tort problems and how new theories may help place old quandaries in sharper focus.  The Symposium will also include a luncheon keynote discussion on the past, present, and future of torts.  Registration for the symposium is available now.

Speakers and moderators at the symposium will include the following:

  • Ronald Aronovsky, Professor of Law, Southwestern Law School;
  • Mark Behrens, Partner and Co-Chair, Public Policy Practice Group, Shook, Hardy & Bacon;
  • John Beisner, Partner and Leader, Mass Torts, Insurance and Consumer Litigation Group, Skadden Arps Slate Meagher & Flom LLP;
  • Alan Calnan, Professor of Law, Southwestern Law School;
  • Fiona Chaney, Investment Manager and Legal Counsel, Bentham IMF;
  • James Fischer, Professor of Law, Southwestern Law School;
  • Manuel Gomez, Associate Dean of International and Graduate Studies and Professor of Law, Florida International University College of Law;
  • Michael Green, Bess and Walter Williams Professor of Law, Wake Forest University School of Law;
  • Gregory Keating, Maurice Jones, Jr. – Class of 1925 Professor of Law and Philosophy, University of Southern California Gould School of Law;
  • Richard Marcus, Coil Chair in Litigation and Distinguished Professor of Law, UC Hastings College of Law;
  • Francis McGovern, Professor of Law, Duke Law School;
  • Linda Mullenix, Morris & Rita Atlas Chair in Advocacy, University of Texas at Austin School of Law;
  • Brian Panish, Founding Partner, Panish, Shea & Boyle;
  • R. Rex Parris, Founding Partner, Parris Law Firm;
  • Christopher Robinette, Professor of Law and Director, Advocacy Certificate Program, Widener University Commonwealth Law School;
  • Michael Sander, Managing Director and Founder, Docket Alarm, and Director, Fastcase Analytics;
  • Victor Schwartz, Partner and Co-Chair, Public Policy Practice Group, Shook, Hardy & Bacon;
  • Anthony Sebok, Professor of Law, Yeshiva University Cardozo School of Law;
  • Catherine Sharkey, Crystal Eastman Professor of Law, New York University School of Law;
  • Kenneth Simons, Chancellor’s Professor of Law, UC Irvine School of Law;
  • Byron Stier, Associate Dean for Strategic Initiatives and Professor of Law, Southwestern Law School;
  • Dov Waisman, Vice Dean and Professor of Law, Southwestern Law School; and
  • Adam Zimmerman, Professor of Law and Gerald Rosen Fellow, Loyola Marymount University Law School Los Angeles.

January 22, 2020 in Aggregate Litigation Procedures, Class Actions, Conferences, Ethics, Lawyers, Mass Tort Scholarship, Preemption, Procedure, Products Liability, Punitive Damages, Science, Trial | Permalink | Comments (0)